Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 83.86

+1.3%

Dec 24 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2750)	5/13/2010 10:44:00 AM
From: Jibacoa	Read Replies (1) of 3722

POZN is up 9.68% with volume of > 290Ks > 1/3 its ADV bigcharts.marketwatch.com Last week it announced results of a PI of PA65020, its combination of enteric-coated aspirin and immediate-release omeprazole, which showed significantly reduction on the incidence of GI mucosal damage vs. enetric coated aspirin alone. Earlier this month the stock had traded above $12 after it anounced that the FDA had approved VIMOVO, its naproxen and esomeprazole magnesium delayed-release tablets for of osteoarthritis, RA, and ankylosing spondylitis. The stock is trading again above $9 but what was previously support is now a good amount of resistance at the $10 level.<g> POZN was able to trim some its loss on the 1stQ in spite of lower revenues. The EE for 2010 & 2011 are around $0.03 & $0.24 on the black vs. the loss of $0.25 last Yr. The ACTAY is $11.75 It seems that with some good news the stock could trade again above $12 <g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next